Actinomycin D (Synonyms: 放线菌素 D; Dactinomycin; Actinomycin IV)

目录号: HY-17559 纯度: 98.55%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Actinomycin D (Dactinomycin) 是一种抗生素 (antibiotic)，发现于小链霉菌 (Streptomyces microsporum)，具有抗菌和抗肿瘤作用。Actinomycin D 是一种 RNA 和蛋白质合成抑制剂，能够抑制细菌的蛋白合成，可以直接结合转录起始复合体中单链或双链 DNA 的鸟嘌呤基团，抑制 DNA 依赖的 RNA 聚合酶活力，干扰 DNA 的转录过程，从而抑制 mRNA 合成。Actinomycin D 抑制 DNA 修复，IC₅₀ 值为 0.42 μM。Actinomycin D 也是一种自噬 (autophagy) 激活剂。Actinomycin D 有望用于癌症和心血管疾病的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 50-76-0

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥490	In-stock
10 mg	￥890	In-stock
50 mg	￥3250	In-stock
100 mg	￥5100	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 610 篇科研文献

RT-PCR

mRNA Stability Assay

: Actinomycin D purchased from MCE. Usage Cited in: Cell. 2024 Apr 25;187(9):2288-2304.e27. [Abstract]; Actinomycin D (0.5 μM) inhibits SLC6A6 KD-induced increase in ATF4 mRNA levels in CD8⁺ T cells.

: Actinomycin D purchased from MCE. Usage Cited in: Cancer Commun (Lond). 2024 Mar;44(3):361-383. [Abstract]; The decay rate of NAT10 mRNA after treatment with actinomycin D ( 5 μg/mL; 2-10 h) in A498 and 786‐O cells with NAT10 knockdown or overexpression (n = 3) (t‐test for statistics).

: Actinomycin D purchased from MCE. Usage Cited in: ACS Nano. 2024 Aug 28. [Abstract]; Actinomycin D (5 μg/mL; 1-4 h) inhibits global mRNA transcription synthesis in HT22 cells.
TFEB mRNA stability in OE NR_030777 HT22 cells upon CoNPs treatment.

: Actinomycin D purchased from MCE. Usage Cited in: Cancer Commun (Lond). 2021 Jan 21. [Abstract]; BAALC‐AS1 knockdown reduced the stability of c‐Myc mRNA. si/BAALC‐AS1‐transfected KYSE‐450 cells were treated with 5 μg/mL actinomycin D for the indicated times. Relative c‐Myc mRNA expression levels were detected by RT‐qPCR. siNC‐transfected KYSE‐450 cells were used as control.

: Actinomycin D purchased from MCE. Usage Cited in: ACS Nano. 2021 Jan 26;15(1):1519-1538. [Abstract]; TFAM and TOM20 protein levels in HK-2 cells detected using Western blot. Cells were stimulated with H2O2 (0.4 mM) and treated with EVs (∼5.8 × 109 particles/mL) followed by either Act-D (0.1 μg/mL) for 4 and 24 h, respectively

: Actinomycin D purchased from MCE. Usage Cited in: Cell Death Dis. 2019 May 21;10(6):395. [Abstract]; Actinomycin D ( Act D; 5μg/ml; 0.5, 1, 2, 4 h) increases the expression of Mcl-1 protein.

: Actinomycin D purchased from MCE. Usage Cited in: Cancer Lett. 2017 Oct 28;407:45-56. [Abstract]; UM-SCC6 and UM-SCC6H cells are treated with Actinomycin D (ActD 5 μg/mL) for the indicated times. The IGF2 mRNA level is measured by RT-PCR.

Actinomycin D 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
纯度 & 产品资料
参考文献

生物活性

Actinomycin D (Dactinomycin) is an antibiotic found in Streptomyces microsporum with antibacterial and anti-tumor effects. Actinomycin D is an inhibitor of RNA and protein synthesis. Actinomycin D can inhibit the protein synthesis of bacteria, directly bind to the guanine groups of single-stranded or double-stranded DNA in the transcriptional initiation complex, inhibit the activity of DNA-dependent RNA polymerase, and interfere with the transcription process of DNA, thereby inhibiting mRNA synthesis. Actinomycin D inhibits DNA repair with an IC₅₀ value of 0.42 μM. Actinomycin D is also an autophagy activator. Actinomycin D is promising for research of cancer and cardiovascular diseases^[1]^[2]^[3]^[4]^[5]^[6]^[7].

IC₅₀ & Target

IC50: 0.42 μM (DNA repair)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
5637	IC₅₀	0.003 μM Compound: AMD	Antiproliferative activity against human 5637 cell line by MTT assay Antiproliferative activity against human 5637 cell line by MTT assay	[PMID: 16913700]
A2780	IC₅₀	1 ng/mL Compound: actinomycin D	Cytotoxicity against human A2780 cells by clonogenic assay Cytotoxicity against human A2780 cells by clonogenic assay	[PMID: 16499334]
A549	EC₅₀	0.201 nM Compound: D	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 27736087]
A549	IC₅₀	0.8 x 10^-2 μM Compound: C1	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	3.8 μM Compound: 1	Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
A549	IC₅₀	7.2 nM Compound: C1	Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
A549	IC₅₀	7.2 nM Compound: C1	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
ACHN	IC₅₀	0.005 μM Compound: AMD	Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
ACHN	IC₅₀	0.005 μM Compound: AMD	Antiproliferative activity against human ACHN cell line by MTT assay Antiproliferative activity against human ACHN cell line by MTT assay	[PMID: 16913700]
BEAS-2B	IC₅₀	0.7 μM Compound: 1	Cytotoxicity against human BEAS-2B cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human BEAS-2B cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
C8166	IC₅₀	0.0008 μM Compound: AMD	Antiproliferative activity against human C8166 cell line by MTT assay Antiproliferative activity against human C8166 cell line by MTT assay	[PMID: 16913700]
Ca-Ski	ED₅₀	1.9 ng/mL Compound: Actinomycin D	Cytotoxicity against human CaSki cells after 6 days by MTT assay Cytotoxicity against human CaSki cells after 6 days by MTT assay	[PMID: 9917310]
Ca-Ski	ED₅₀	1.9 ng/mL Compound: actinomycin D	Cytotoxicity against human CaSKi cells after 6 days by MTT assay Cytotoxicity against human CaSKi cells after 6 days by MTT assay	[PMID: 10785428]
Ca-Ski	ED₅₀	1.9 ng/mL Compound: actinomycin D	Cytotoxicity against human CaSki cells after 6 days by MTT assay Cytotoxicity against human CaSki cells after 6 days by MTT assay	[PMID: 10425143]
Ca-Ski	ED₅₀	1.9 ng/mL Compound: actinomycin D	Cytotoxicity against human CaSKi cells by MTT assay Cytotoxicity against human CaSKi cells by MTT assay	[PMID: 11908984]
CCRF-CEM	IC₅₀	0.001 μM Compound: AMD	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-CEM	IC₅₀	0.001 μM Compound: AMD	Antiproliferative activity against human CCRF-CEM cell line by MTT assay Antiproliferative activity against human CCRF-CEM cell line by MTT assay	[PMID: 16913700]
CCRF-CEM	IC₅₀	1.6 nM Compound: actinomycin D	Cytotoxicity against human CCRF-CEM cells after 72 hrs Cytotoxicity against human CCRF-CEM cells after 72 hrs	[PMID: 18329887]
CCRF-SB	IC₅₀	0.002 μM Compound: AMD	Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-SB	IC₅₀	0.002 μM Compound: AMD	Antiproliferative activity against human CCRF-SB cell line by MTT assay Antiproliferative activity against human CCRF-SB cell line by MTT assay	[PMID: 16913700]
G-361	IC₅₀	0.001 μM Compound: AMD	Antiproliferative activity against human G361 cell line by MTT assay Antiproliferative activity against human G361 cell line by MTT assay	[PMID: 16913700]
G-361	IC₅₀	0.006 μM Compound: AMD	Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HEK293	IC₅₀	9 μM Compound: 1	Inhibition of human DDR2 expressed in HEK293 cells assessed as reduction in collagen-1-induced DDR2 tyrosine phosphorylation pre-incubated for 30 mins by immunoblotting method Inhibition of human DDR2 expressed in HEK293 cells assessed as reduction in collagen-1-induced DDR2 tyrosine phosphorylation pre-incubated for 30 mins by immunoblotting method	[PMID: 25569119]
HeLa	IC₅₀	0.001 μM Compound: actinomycin D	Cytotoxicity against human HeLa cells in log-phase after 48 hrs by MTT assay Cytotoxicity against human HeLa cells in log-phase after 48 hrs by MTT assay	[PMID: 16309323]
HeLa	IC₅₀	0.008 μM Compound: AMD	Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HeLa	IC₅₀	0.01 μg/mL Compound: Actinomycin D	Cytotoxicity against human HeLa cells after 3 days by methylene blue assay Cytotoxicity against human HeLa cells after 3 days by methylene blue assay	[PMID: 9644081]
HeLa	IC₅₀	0.011 μM Compound: actinomycin D	Cytotoxicity against human HeLa cells in lag-phase after 48 hrs by MTT assay Cytotoxicity against human HeLa cells in lag-phase after 48 hrs by MTT assay	[PMID: 16309323]
HeLa	IC₅₀	0.04 μM Compound: AMD	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 16913700]
HeLa	IC₅₀	0.12 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
HeLa	IC₅₀	0.4 nM Compound: Actinomycin D	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 18461997]
HeLa	IC₅₀	1.1 nM Compound: C1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	1.1 nM Compound: C1	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
HeLa	IC₅₀	1.1 nM Compound: Actinomycin D	Cytotoxicity against human HeLa cells in lag phase of growth after 48 hrs Cytotoxicity against human HeLa cells in lag phase of growth after 48 hrs	[PMID: 24709561]
HeLa	IC₅₀	1.6 nM Compound: Actinomycin D	Cytotoxicity against human HeLa cells in log phase of growth after 48 hrs Cytotoxicity against human HeLa cells in log phase of growth after 48 hrs	[PMID: 24709561]
HeLa	IC₅₀	262.4 nM Compound: ActD	Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting	[PMID: 20118940]
HeLa	IC₅₀	3.2 nM Compound: C1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
HeLa	IC₅₀	519.7 nM Compound: ActD	Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy	[PMID: 20118940]
Hep 3B2	IC₅₀	0.01 μg/mL Compound: Actinomycin D	Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay	[PMID: 9644081]
HEp-2	IC₅₀	0.004 μM Compound: AMD	Antiproliferative activity against human Hep2 cell line by MTT assay Antiproliferative activity against human Hep2 cell line by MTT assay	[PMID: 16913700]
HEp-2	IC₅₀	0.006 μM Compound: actinomycin D	Cytotoxicity against human Hep2 cells in log-phase after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells in log-phase after 48 hrs by MTT assay	[PMID: 16309323]
HEp-2	IC₅₀	0.191 μM Compound: actinomycin D	Cytotoxicity against human Hep2 cells in lag-phase after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells in lag-phase after 48 hrs by MTT assay	[PMID: 16309323]
HEp-2	IC₅₀	1.7 x 10^-1 μM Compound: Actinomycin D	Cytotoxicity against human Hep2 cells in lag phase of growth after 48 hrs Cytotoxicity against human Hep2 cells in lag phase of growth after 48 hrs	[PMID: 24709561]
HEp-2	IC₅₀	6.2 nM Compound: Actinomycin D	Cytotoxicity against human Hep2 cells in log phase of growth after 48 hrs Cytotoxicity against human Hep2 cells in log phase of growth after 48 hrs	[PMID: 24709561]
HepG2	IC₅₀	0.01 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
HepG2	GI₅₀	1 μM Compound: actinomycin D	Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine assay Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine assay	[PMID: 10757717]
HL-60	IC₅₀	0.02 μM Compound: 1	Cytotoxicity against human HL-60 cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
HT-29	IC₅₀	0.006 μM Compound: AMD	Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HT-29	IC₅₀	0.006 μM Compound: AMD	Antiproliferative activity against human HT29 cell line by MTT assay Antiproliferative activity against human HT29 cell line by MTT assay	[PMID: 16913700]
HT-29	IC₅₀	2.9 nM Compound: Actinomycin D	Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay	[PMID: 18461997]
HT-29	IC₅₀	223 nM Compound: Actinomycin D	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
HT-3	ED₅₀	5.6 x 10^-4 μg/mL Compound: Actinomycin D	Cytotoxicity against human HT-3 cells after 6 days by MTT assay Cytotoxicity against human HT-3 cells after 6 days by MTT assay	[PMID: 9917310]
HT-3	ED₅₀	5.6 x 10^-4 μg/mL Compound: actinomycin D	Cytotoxicity against human HT3 cells after 6 days by MTT assay Cytotoxicity against human HT3 cells after 6 days by MTT assay	[PMID: 10785428]
HT-3	ED₅₀	5.6 x 10^-4 μg/mL Compound: actinomycin D	Cytotoxicity against human HT-3 cells after 6 days by MTT assay Cytotoxicity against human HT-3 cells after 6 days by MTT assay	[PMID: 10425143]
Jurkat	IC₅₀	0.0045 μM Compound: Actinomycin D	Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours	[PMID: 11052798]
KB	IC₅₀	0.001 μM Compound: AMD	Antiproliferative activity against human KB cell line by MTT assay Antiproliferative activity against human KB cell line by MTT assay	[PMID: 16913700]
KB	IC₅₀	0.004 μM Compound: Actinomycin D	Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	0.005 μM Compound: AMD	Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50% Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%	[PMID: 12431048]
KB	IC₅₀	0.01 μg/mL Compound: Actinomycin D	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 12502326]
KB	IC₅₀	0.01 μg/mL Compound: Actinomycin D	Cytotoxicity against human KB cells after 72 hrs by methylene blue assay Cytotoxicity against human KB cells after 72 hrs by methylene blue assay	[PMID: 11473432]
KB	IC₅₀	0.05 μM Compound: Actinomycin D	Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	0.2 μM Compound: Actinomycin D	Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	0.2 μM Compound: Actinomycin D	Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method	[PMID: 14761187]
L02	IC₅₀	0.5 μM Compound: 1	Cytotoxicity against human L02 cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human L02 cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
L1210	ED₅₀	0.009 μM Compound: 1	Inhibition of RNA synthesis in mouse L1210 cells assessed as [3H]-uridine incorporation preincubated for 3 hrs before [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis Inhibition of RNA synthesis in mouse L1210 cells assessed as [3H]-uridine incorporation preincubated for 3 hrs before [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis	[PMID: 330857]
L1210	ED₅₀	0.015 μM Compound: 1	Inhibition of RNA synthesis in mouse L1210 cells by [3H]-uridine incorporation assay Inhibition of RNA synthesis in mouse L1210 cells by [3H]-uridine incorporation assay	[PMID: 573799]
L1210	ED₅₀	0.4 μM Compound: 1	Inhibition of DNA synthesis in mouse L1210 cells assessed as [3H]-thymidine incorporation preincubated for 3 hrs before [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis Inhibition of DNA synthesis in mouse L1210 cells assessed as [3H]-thymidine incorporation preincubated for 3 hrs before [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis	[PMID: 330857]
L1210	ED₅₀	0.6 μM Compound: 1	Inhibition of DNA synthesis in mouse L1210 cells by [3H]-thymidine incorporation assay Inhibition of DNA synthesis in mouse L1210 cells by [3H]-thymidine incorporation assay	[PMID: 573799]
MCF7	IC₅₀	0.006 μM Compound: AMD	Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
MCF7	IC₅₀	0.103 μM Compound: actinomycin D	Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay	[PMID: 20704331]
MCF7	IC₅₀	0.2 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
MCF7	GI₅₀	0.5 μM Compound: actinomycin D	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine assay	[PMID: 10757717]
MCF7	IC₅₀	2.4 x 10^-2 μM Compound: C1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MCF7	IC₅₀	2.4 x 10^-2 μM Compound: C1	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
MCF7	IC₅₀	4.8 x 10^-2 μM Compound: C1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
MOLT-3	IC₅₀	< 1 μM Compound: Actinomycin D	Cytotoxicity against MOLT3 Leukemia cells by MTS assay Cytotoxicity against MOLT3 Leukemia cells by MTS assay	[PMID: 16420056]
MOLT-3	IC₅₀	≤ 1 μM Compound: Actinomycin D	Cytotoxicity against human MOLT3 cells after 20 hrs by MTS assay Cytotoxicity against human MOLT3 cells after 20 hrs by MTS assay	[PMID: 21093966]
MOLT-4	IC₅₀	0.001 μM Compound: AMD	Antiproliferative activity against human MOLT4 cell line by MTT assay Antiproliferative activity against human MOLT4 cell line by MTT assay	[PMID: 16913700]
MT4	IC₅₀	0.0009 μM Compound: AMD	Antiproliferative activity against human MT4 cell line by MTT assay Antiproliferative activity against human MT4 cell line by MTT assay	[PMID: 16913700]
MT4	IC₅₀	0.001 μM Compound: AMD	Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
NCI-H460	IC₅₀	0.008 μM Compound: actinomycin D	Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay	[PMID: 20704331]
P388	ED₅₀	0.046 μM Compound: AMD	Concentration required for 50% inhibition of incorporation of labeled uridine by P388 cells for the synthesis of RNA (in vitro) Concentration required for 50% inhibition of incorporation of labeled uridine by P388 cells for the synthesis of RNA (in vitro)	[PMID: 6169834]
P388	IC₅₀	0.2 nM Compound: Actinomycin D	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
P388	ED₅₀	0.996 μM Compound: AMD	Concentration required for 50% inhibition of incorporation of labeled thymidine by p388 cells for synthesis of DNA (in vitro) Concentration required for 50% inhibition of incorporation of labeled thymidine by p388 cells for synthesis of DNA (in vitro)	[PMID: 6169834]
PC-3	EC₅₀	0.276 nM Compound: D	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 27736087]
PLC-PRF-5	ED₅₀	1.4 ng/mL Compound: Actinomycin D	Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay	[PMID: 9917310]
PLC-PRF-5	ED₅₀	1.4 ng/mL Compound: actinomycin D	Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay	[PMID: 10785428]
PLC-PRF-5	ED₅₀	1.4 ng/mL Compound: actinomycin D	Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay	[PMID: 10425143]
RKO	IC₅₀	0.03 μM Compound: 1	Cytotoxicity against human RKO cells assessed as growth inhibition incubated for 68 hrs by MTT assay Cytotoxicity against human RKO cells assessed as growth inhibition incubated for 68 hrs by MTT assay	[PMID: 34270246]
SF-268	IC₅₀	0.016 μM Compound: actinomycin D	Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay	[PMID: 20704331]
SiHa	ED₅₀	8.1 x 10^-4 μg/mL Compound: Actinomycin D	Cytotoxicity against human SiHa cells after 6 days by MTT assay Cytotoxicity against human SiHa cells after 6 days by MTT assay	[PMID: 9917310]
SiHa	ED₅₀	8.1 x 10^-4 μg/mL Compound: actinomycin D	Cytotoxicity against human SiHa cells after 6 days by MTT assay Cytotoxicity against human SiHa cells after 6 days by MTT assay	[PMID: 10785428]
SiHa	ED₅₀	8.1 x 10^-4 μg/mL Compound: actinomycin D	Cytotoxicity against human SiHa cells after 6 days by MTT assay Cytotoxicity against human SiHa cells after 6 days by MTT assay	[PMID: 10425143]
SiHa	ED₅₀	8.1 x 10^-4 μg/mL Compound: actinomycin D	Cytotoxicity against human SiHa cells by MTT assay Cytotoxicity against human SiHa cells by MTT assay	[PMID: 11908984]
SK-MEL-28	IC₅₀	0.002 μM Compound: AMD	Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
T-24	ED₅₀	1.5 ng/mL Compound: Actinomycin D	Cytotoxicity against human T24 cells after 6 days by MTT assay Cytotoxicity against human T24 cells after 6 days by MTT assay	[PMID: 9917310]
T-24	ED₅₀	1.5 ng/mL Compound: actinomycin D	Cytotoxicity against human T24 cells after 6 days by MTT assay Cytotoxicity against human T24 cells after 6 days by MTT assay	[PMID: 10785428]
T-24	ED₅₀	1.5 ng/mL Compound: actinomycin D	Cytotoxicity against human T24 cells after 6 days by MTT assay Cytotoxicity against human T24 cells after 6 days by MTT assay	[PMID: 10425143]
U2OS	IC₅₀	3.2 nM Compound: Actinomycin D	Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay	[PMID: 18461997]
U-937	IC₅₀	< 1 μM Compound: Actinomycin D	Cytotoxicity against U937 Lymphoma cells by MTS assay Cytotoxicity against U937 Lymphoma cells by MTS assay	[PMID: 16420056]
Vero	IC₅₀	0.001 μM Compound: actinomycin D	Cytotoxicity against african green monkey Vero cells in log-phase after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells in log-phase after 48 hrs by MTT assay	[PMID: 16309323]
Vero	IC₅₀	0.071 μM Compound: actinomycin D	Cytotoxicity against african green monkey Vero cells in lag-phase after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells in lag-phase after 48 hrs by MTT assay	[PMID: 16309323]
Vero	IC₅₀	1 x 10^-2 μM Compound: Actinomycin D	Cytotoxicity against African green monkey Vero cells in log phase of growth after 48 hrs Cytotoxicity against African green monkey Vero cells in log phase of growth after 48 hrs	[PMID: 24709561]
Vero	IC₅₀	1.1 x 10^-2 μM Compound: C1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	11 μM Compound: Actinomycin D	Cytotoxicity against african green monkey Vero cells after 20 hrs by MTS assay Cytotoxicity against african green monkey Vero cells after 20 hrs by MTS assay	[PMID: 21093966]
Vero	IC₅₀	11 μM Compound: Actinomycin D	Cytotoxicity against normal vero kidney cells by MTS assay Cytotoxicity against normal vero kidney cells by MTS assay	[PMID: 16420056]
Vero	IC₅₀	7.1 x 10^-2 μM Compound: C1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay	[PMID: 28923386]
Vero	IC₅₀	7.1 x 10^-2 μM Compound: C1	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 22705001]
Vero	IC₅₀	7.2 x 10^-2 μM Compound: Actinomycin D	Cytotoxicity against African green monkey Vero cells in lag phase of growth after 48 hrs Cytotoxicity against African green monkey Vero cells in lag phase of growth after 48 hrs	[PMID: 24709561]
WIL2-NS	IC₅₀	0.003 μM Compound: AMD	Antiproliferative activity against human Wil2-NS cells by MTT assay Antiproliferative activity against human Wil2-NS cells by MTT assay	[PMID: 16913700]

体外研究
(In Vitro)

Actinomycin D (80 nM-8 μM, 18-24 小时) 抑制血管平滑肌细胞的增殖，使细胞周期阻滞在 G1 期^[2]。
Actinomycin D (1-100 ng/mL, 24-96 小时) 诱导细胞凋亡，抑制 PANC-1 胰腺癌细胞^[4]。
Actinomycin D (0.02-0.08 μM, 48 小时) 诱导慢性淋巴细胞白血病 (CLL) 细胞凋亡^[5]。
注意事项：
1. 传代次数、细胞状态、细胞密度都可能会影响实验效果。需要调整细胞状态至较好时开展实验 (HCT 116 贴壁细胞形态较小，密度大时容易聚团，铺细胞尽量均匀);
2. 不同细胞系对 Actinomycin D 敏感度不同，检测指标可能有差异，建议参考文献，提前做预实验 (摸索药物处理时间、浓度，抗体条件)，确定实验方案合理可行；
注：Act D 在较低浓度下 (CCK8) 和短时间 (WB) 内作用效果明显；浓度的微小变化也能引起细胞活力 (48 h) 较大的改变，而浓度过高时细胞活力上升，时间过长会反而会抑制 MDM2 和 p53 的表达。建议预实验的检测指标多一点，成功概率高。
3. 药物现配现用，可超声助溶，直至溶液澄清透明; 首次实验用不完时需分装冻存 -20℃，避免反复冻融；
4. Actinomycin D 具有细胞毒性，配制和使用过程中需在通风良好的环境中进行，注意防护；应避光、低温保存，避免其分解失效。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	Pancreatic cancer cells
Concentration:	1-100 ng/mL
Incubation Time:	24-96 h
Result:	Caused apoptosis and decreased the cell growth in PANC-1 cells.

体内研究
(In Vivo)

Actinomycin D (0.06 mg/kg, 腹腔注射，连续 14 天) 导致慢性淋巴细胞白血病小鼠模型肿瘤消退^[5]。
Actinomycin D (0.05-0.12 mg/kg, 静脉注射或心肌内注射, 在缺血预处理前 15 分钟和两次再灌注周期内或缺血预处理前 40 分钟和两次再灌注周期内) 可增加雄性去势猪缺血预处理诱导的心肌梗死面积，并降低缺血预处理诱导的心肌保护作用^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse model of chronic lymphocytic leukemia^[6]
Dosage:	0.06 mg/kg
Administration:	i.p., 14 consecutive days
Result:	Prolonged the survival time of mice model of chronic lymphocytic leukemia.

分子量

1255.42

Formula

C₆₂H₈₆N₁₂O₁₆

CAS 号

50-76-0

性状

固体

颜色

Orange to red

中文名称

放线菌素 D

结构分类

初始来源

微生物

Streptomyces

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (79.65 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.7965 mL	3.9827 mL	7.9655 mL
5 mM	0.1593 mL	0.7965 mL	1.5931 mL
10 mM	0.0797 mL	0.3983 mL	0.7965 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.99 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (1.66 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.58%

选择批次：

Data Sheet (684 KB) SDS (644 KB)

COA (302 KB) LCMS (437 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Barret JM, et al. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplateassay. Carcinogenesis. 1997 Dec;18(12):2441-5. [Content Brief]

[2]. Wu CH, et al. The molecular mechanism of actinomycin D in preventing neointimal formation in rat carotid arteries after balloon injury. J Biomed Sci. 2005;12(3):503-12. [Content Brief]

[3]. Merkel O, et al. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2508-16. [Content Brief]

[4]. Kleeff J, et al. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer. 2000 May 1;86(3):399-407. [Content Brief]

[5]. Merkel O, et al. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. Leukemia. 2012 Dec;26(12):2508-16. [Content Brief]

[6]. Strohm C, et al. Transcription inhibitor actinomycin-D abolishes the cardioprotective effect of ischemic reconditioning. Cardiovasc Res. 2002 Aug 15;55(3):602-18. [Content Brief]

[7]. Schwartz HS, et al. Actinomycin D: effects on Ridgway osteogenic sarcoma in mice. Cancer Res. 1966 Sep;26(9):1873-9. [Content Brief]

Actinomycin D 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.7965 mL	3.9827 mL	7.9655 mL	19.9137 mL
	5 mM	0.1593 mL	0.7965 mL	1.5931 mL	3.9827 mL
	10 mM	0.0797 mL	0.3983 mL	0.7965 mL	1.9914 mL
	15 mM	0.0531 mL	0.2655 mL	0.5310 mL	1.3276 mL
	20 mM	0.0398 mL	0.1991 mL	0.3983 mL	0.9957 mL
	25 mM	0.0319 mL	0.1593 mL	0.3186 mL	0.7965 mL
	30 mM	0.0266 mL	0.1328 mL	0.2655 mL	0.6638 mL
	40 mM	0.0199 mL	0.0996 mL	0.1991 mL	0.4978 mL
	50 mM	0.0159 mL	0.0797 mL	0.1593 mL	0.3983 mL
	60 mM	0.0133 mL	0.0664 mL	0.1328 mL	0.3319 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Actinomycin D50-76-0Dactinomycin Actinomycin IV放线菌素 DDNA/RNA SynthesisAutophagyBacterialApoptosisAntibioticDNArepairtranscriptionreplicationInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Actinomycin D (Synonyms: 放线菌素 D; Dactinomycin; Actinomycin IV)

Customer Review

MCE 顾客使用本产品发表的 610 篇科研文献

Actinomycin D 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Actinomycin D 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Actinomycin D (Synonyms: 放线菌素 D; Dactinomycin; Actinomycin IV)

Customer Review

Actinomycin D 相关抗体

MCE 顾客使用本产品发表的 610 篇科研文献

Actinomycin D 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Actinomycin D 相关抗体:

摩尔计算器

稀释计算器

Actinomycin D 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z